Get the Stockscreener App
4.86
25.91%
1.00
After Hours:
4.70
-0.16
-3.29%
Perspective Therapeutics Inc stock is traded at $4.86, with a volume of 5.61M.
It is up +25.91% in the last 24 hours and up +50.46% over the past month.
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
See More
Previous Close:
$3.86
Open:
$4.2
24h Volume:
5.61M
Relative Volume:
6.59
Market Cap:
$360.92M
Revenue:
$6.96M
Net Income/Loss:
$-46.51M
P/E Ratio:
-28.32
EPS:
-0.1716
Net Cash Flow:
$-37.99M
1W Performance:
+33.52%
1M Performance:
+50.46%
6M Performance:
+161.29%
1Y Performance:
-63.32%
1-Day Range:
$4.08
$5.30
1-Week Range:
$3.37
$5.30
52-Week Range:
$1.60
$13.19
Perspective Therapeutics Inc Stock (CATX) Company Profile
Name
Perspective Therapeutics Inc
Sector
Industry
Phone
509-375-1202
Address
350 Hills Street, Suite 106, Richland
Compare CATX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
4.86 | 286.66M | 6.96M | -46.51M | -37.99M | -0.1716 |
|
ABT
Abbott Laboratories
|
132.57 | 232.02B | 43.11B | 13.94B | 6.78B | 7.9963 |
|
BSX
Boston Scientific Corp
|
95.41 | 144.14B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
364.60 | 141.53B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
95.45 | 123.78B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
73.94 | 44.14B | 5.69B | 1.41B | 577.90M | 6.9828 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | H.C. Wainwright | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-01-24 | Initiated | Wedbush | Outperform |
| Sep-25-24 | Initiated | Truist | Buy |
| Jul-25-24 | Initiated | BofA Securities | Buy |
| May-09-24 | Initiated | Cantor Fitzgerald | Overweight |
View All
Perspective Therapeutics Inc Stock (CATX) Latest News
Using Bollinger Bands to evaluate Perspective Therapeutics Inc.Oil Prices & Consistent Growth Equity Picks - newser.com
Can Perspective Therapeutics Inc. rally from current levelsJuly 2025 Chart Watch & Reliable Momentum Entry Alerts - newser.com
Has Perspective Therapeutics Inc. found a price floor2025 Buyback Activity & Entry Point Confirmation Alerts - newser.com
Will Perspective Therapeutics Inc. see short term momentumJuly 2025 Short Interest & Risk Controlled Swing Alerts - newser.com
This Aptiv Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
BTIG initiates coverage on Perspective Therapeutics stock with Buy rating By Investing.com - Investing.com Nigeria
BTIG Research Initiates Coverage on Perspective Therapeutics With Buy Rating, $14 Price Target - MarketScreener
BTIG initiates coverage on Perspective Therapeutics stock with Buy rating - Investing.com India
BTIG Initiates Coverage on CATX with a Buy Rating and $14 Target | CATX Stock News - GuruFocus
Perspective Therapeutics Inc. stock momentum explainedWeekly Loss Report & Verified Momentum Stock Ideas - newser.com
Technical analysis overview for Perspective Therapeutics Inc. stock - newser.com
Will Perspective Therapeutics Inc. stock outperform small cap peers2025 Market Outlook & Intraday High Probability Setup Alerts - newser.com
Real time social sentiment graph for Perspective Therapeutics Inc.Quarterly Earnings Summary & Free Accurate Trade Setup Notifications - newser.com
How robust is Perspective Therapeutics Inc. stock financial positionJuly 2025 Decliners & Verified Momentum Stock Ideas - newser.com
Why Perspective Therapeutics Inc. (AAJ0) stock stays undervaluedTrade Signal Summary & Long-Term Safe Investment Plans - newser.com
How dovish Fed policy supports Perspective Therapeutics Inc. (AAJ0) stock2025 Technical Overview & Risk Adjusted Buy/Sell Alerts - newser.com
Will Perspective Therapeutics Inc. rebound enough to break evenWeekly Gains Summary & High Conviction Trade Alerts - newser.com
Candlestick signals on Perspective Therapeutics Inc. stock todayTreasury Yields & AI Powered Market Entry Strategies - newser.com
Volatility clustering patterns for Perspective Therapeutics Inc.Portfolio Update Report & Risk Adjusted Swing Trade Ideas - newser.com
Will Perspective Therapeutics Inc. stock go up soonMarket Sentiment Review & Safe Capital Growth Stock Tips - newser.com
Top chart patterns to watch in Perspective Therapeutics Inc.2025 Market Trends & Verified Entry Point Signals - newser.com
Perspective Therapeutics Inc. stock outlook for YEARMarket Trend Summary & Daily Technical Forecast Reports - newser.com
Can Perspective Therapeutics Inc. stock reach $200 price target2025 Big Picture & High Conviction Buy Zone Picks - newser.com
Analyzing Perspective Therapeutics Inc. with risk reward ratio charts2025 Key Lessons & Safe Entry Trade Signal Reports - newser.com
Applying Elliott Wave Theory to Perspective Therapeutics Inc.Gap Up & Free Fast Entry Momentum Trade Alerts - newser.com
What drives Perspective Therapeutics Inc AAJ0 stock priceMoving Average Crossovers & Free Record-Breaking Gains - earlytimes.in
Perspective Therapeutics, Inc. Common Stock (NYSE:CATX) Stock Quote - FinancialContent
How Perspective Therapeutics Inc. (AAJ0) stock valuation compares with sectorMarket Activity Report & Safe Entry Momentum Tips - newser.com
Heatmap analysis for Perspective Therapeutics Inc. and competitorsTrend Reversal & Safe Entry Momentum Tips - newser.com
Is Perspective Therapeutics Inc. (AAJ0) stock included in top ETFsIPO Watch & Risk Managed Investment Strategies - newser.com
Is Perspective Therapeutics Inc. stock attractive for retirement portfoliosWeekly Stock Recap & Consistent Growth Equity Picks - newser.com
Is Perspective Therapeutics Inc. stock a smart buy before Fed meetingJuly 2025 Movers & Smart Swing Trading Techniques - newser.com
What earnings revisions data tells us about Perspective Therapeutics Inc.July 2025 News Drivers & Weekly Breakout Opportunity Watchlist - newser.com
Perspective Therapeutics (NYSE:CATX) Receives Outperform Rating from Wedbush - Defense World
Perspective Therapeutics (NYSE:CATX) Given Buy Rating at HC Wainwright - Defense World
HC Wainwright Reiterates Buy Rating for Perspective Therapeutics (NYSE:CATX) - MarketBeat
CATX: HC Wainwright & Co. Reiterates Buy Rating with $10 Target - GuruFocus
HC Wainwright & Co. Reiterates Perspective Therapeutics (CATX) Buy Recommendation - Nasdaq
H.C. Wainwright reiterates Buy rating on Perspective Therapeutics stock - Investing.com
Why Perspective Therapeutics Inc. (AAJ0) stock is favored by hedge fundsEarnings Risk Report & Precise Trade Entry Recommendations - newser.com
Is Perspective Therapeutics Inc. stock ready for a breakoutMarket Activity Summary & AI Driven Stock Price Forecasts - newser.com
Perspective Therapeutics Announces First Patient Dosed with - GlobeNewswire
Can Perspective Therapeutics Inc. stock sustain margin levelsWeekly Trading Summary & Expert Verified Movement Alerts - newser.com
Can Perspective Therapeutics Inc. (AAJ0) stock sustain free cash flowJuly 2025 Fed Impact & Real-Time Chart Pattern Alerts - newser.com
Long term hold vs stop loss in Perspective Therapeutics Inc.Market Risk Analysis & Growth Focused Entry Reports - newser.com
What macro factors could drive Perspective Therapeutics Inc. (AAJ0) stock higherEntry Point & High Return Trade Guides - newser.com
Sector ETF performance correlation with Perspective Therapeutics Inc.Market Growth Summary & Fast Gain Swing Trade Alerts - newser.com
Perspective Therapeutics Inc Stock (CATX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.83%
Cap:
|
Volume (24h):